Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.74 |
| ▸ | XDH | P47989 | 6/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141928 | 0.85 | BACE1 (1.00) | BACE1XDHCYP3A4BLM | |
| SCHEMBL4142291 | 0.81 | BACE1 (0.75) | BACE1XDHABL1RIN1CYP3A4 | |
| SCHEMBL4134277 | 0.81 | BACE1 (0.79) | BACE1XDH | |
| SCHEMBL4139678 | 0.80 | BACE1 (1.00) | BACE1XDHABL1RIN1CYP3A4 | |
| SCHEMBL4142794 | 0.79 | BACE1 (0.73) | BACE1XDHABL1RIN1CYP3A4 | |
| SCHEMBL4142212 | 0.79 | BACE1 (0.76) | BACE1XDH | |
| SCHEMBL4136769 | 0.79 | BACE1 (0.72) | BACE1XDHCYP3A4BLMNOS1 | |
| SCHEMBL4146920 | 0.76 | BACE1 (0.68) | BACE1XDHABL1RIN1 | |
| SCHEMBL5907152 | 0.74 | BACE1 (0.74) | BACE1XDHCYP3A4BLM | |
| SCHEMBL4141246 | 0.73 | BACE1 (0.62) | BACE1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885XDH 951/4885ABL1 2655/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885XDH 259/4885ABL1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.